peptideInjectablePrescription only (US)Gonadorelin products (e.g., Factrel, Lutrepulse) were FDA-approved for diagnostic pituitary testing and pulsatile treatment of hypothalamic amenorrhea; US commercial availability of branded products has since narrowedOff-label pulsatile use for hypogonadotropic hypogonadism is documented mainly outside the US in the cited cohorts
GonadorelinBenefits, Dosage & Interactions
Also known as: GnRH
Gonadorelin is a synthetic decapeptide (a peptide consisting of ten amino acids) that is structurally and functionally identical to the naturally occurring gonadotropin-releasing hormone (GnRH). GnRH is produced by the hypothalamus in the brain and plays a crucial role in regulating the reproductive system.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Limited — Human observational or case data only — no randomized trials.
Evidence strengthLimited · 2/4
PreclinicalStrong human evidence
Human observational or case data only — no randomized trials.
Plasma half-life
10–40 min (human, secondary source — not label-verified)
Default unit
mcg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Pulsatile gonadorelin protocols in these cohorts used low microgram doses delivered on a pulsatile schedule via infusion pump[1][2]
Reported for Gonadorelin in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Gonadorelin entry is written from. Each number matches an inline marker above.
- [1]Efficacy and safety of pulsatile GnRH pump therapy in male infants with congenital hypogonadotropic hypogonadismWang X, Zhang ZX, Chen J, Fu D, Du M, Chen Y, Wei H · Endocrine Connections · 2025 · Peer-reviewed · PMID 40099791
- [2]Changes in Bone Mineral Density and Metabolic Parameters after Pulsatile Gonadorelin Treatment in Young Men with Hypogonadotropic HypogonadismLi CX, Tang ST, Zhang Q · International Journal of Endocrinology · 2015 · Peer-reviewed · PMID 26417369
How to track Gonadorelin doses
Gonadorelin is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Gonadorelin is stored as a concentration rather than a guess. DoseRoutine converts that into mcg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mcg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Gonadorelin comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
Review Gonadorelin alongside your logged metrics and any relevant blood work every few weeks before changing the dose, so the change is a response to data rather than to a good or bad day.
What to log each time
- Dose in mcg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Gonadorelin dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Gonadorelin studied for?
What is Gonadorelin?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Gonadorelin is a synthetic decapeptide (a peptide consisting of ten amino acids) that is structurally and functionally identical to the naturally occurring gonadotropin-releasing hormone (GnRH). GnRH is produced by the hypothalamus in the brain and plays a crucial role in regulating the reproductive system. It acts as a signaling molecule, stimulating the pituitary gland to release two other important hormones: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones, in turn, control the function of the gonads (testes in males, ovaries in females), influencing processes such as testosterone production, sperm maturation, ovulation, and estrogen production.
Historically, gonadorelin was used diagnostically to assess pituitary function and therapeutically in certain reproductive disorders. Its primary clinical applications have evolved over time with the development of more potent GnRH agonists and antagonists. Gonadorelin is delivered by injection, reflecting its peptide nature which would be degraded if taken orally. Its rapid half-life necessitates specific administration schedules to achieve desired effects. (PubChem, DrugBank)
What does the research say about Gonadorelin?
Tap a section to expand.
Gonadorelin exerts its effects by binding to specific gonadotropin-releasing hormone receptors located on the surface of pituitary cells. This binding initiates a cascade of intracellular events that ultimately lead to the synthesis and release of LH and FSH into the bloodstream. The pulsatile release of natural GnRH is critical for maintaining normal reproductive function; continuous or prolonged exposure to GnRH (or its synthetic analogs) can paradoxically lead to a desensitization of the pituitary receptors, resulting in a downregulation of LH and FSH production. This biphasic effect—initial stimulation followed by inhibition—is a key aspect of GnRH pharmacology.
In physiological conditions, gonadorelin (GnRH) acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. When gonadorelin binds to its receptors, it activates G-protein coupled signaling pathways, primarily involving the phosphoinositide second messenger system. This leads to an increase in intracellular calcium and activation of protein kinase C, which are crucial for the synthesis and secretion of gonadotropins. The pulsatile nature of GnRH release from the hypothalamus is essential for maintaining the sensitivity of pituitary cells to GnRH. If gonadorelin is administered continuously, the pituitary GnRH receptors can become desensitized and downregulated, leading to a reduction in LH and FSH release. This desensitization can be leveraged therapeutically to suppress gonadal hormone production, a mechanism utilized by more potent GnRH agonists in conditions requiring sex hormone deprivation. (DrugBank, NIH)
Source for this section: Sources for How does Gonadorelin work?: Jumps to this entry in the sources and references list at the end of the page.
In its primary role, gonadorelin helps regulate the reproductive system. Its therapeutic applications have primarily focused on diagnostic testing and addressing certain fertility issues. For instance, gonadorelin was used as a diagnostic tool to differentiate between hypothalamic and pituitary causes of hypogonadotropic hypogonadism (a condition where the gonads produce little or no sex hormones due to problems with the hypothalamus or pituitary gland). By administering gonadorelin and observing the LH and FSH response, clinicians could pinpoint the location of the dysfunction.
In certain cases of infertility, especially those linked to deficiencies in GnRH secretion, pulsatile administration of gonadorelin has been studied to induce ovulation in women or stimulate spermatogenesis in men. It has also been explored in the management of delayed puberty.
The concept of body composition and muscle gain is an area that might bring gonadorelin to attention. The HPG axis, regulated by gonadorelin, is intricately linked to sex hormone production, such as testosterone in men. Testosterone plays a significant role in muscle mass and strength. Therefore, compounds that influence this axis, including gonadorelin, could theoretically impact these outcomes. However, the direct use of gonadorelin specifically for muscle gain is not a primary or established therapeutic indication. Its effects on muscle are secondary to its influence on a regulated hormonal axis and would be observed only in the context of correcting a deficiency or stimulating a suppressed system under medical supervision. (MedlinePlus, DrugBank)
Clinical evidence for gonadorelin spans several decades, primarily focusing on its diagnostic and therapeutic utility in reproductive medicine. Studies have demonstrated its effectiveness as a diagnostic agent for evaluating pituitary responsiveness in conditions like hypogonadotropic hypogonadism. For example, a single intravenous injection of gonadorelin can differentiate between primary pituitary failure and hypothalamic insufficiency based on the subsequent rise in LH and FSH levels (NIH).
In therapeutic contexts, evidence supports the use of pulsatile gonadorelin administration for inducing ovulation in selective cases of anovulation caused by hypothalamic dysfunction. Studies, often controlled trials, have shown success rates in ovulation induction and subsequent pregnancies in women with specific forms of infertility (Cochrane Review). Similarly, the use of pulsatile gonadorelin has been investigated for stimulating testicular function and spermatogenesis in men with hypogonadotropic hypogonadism, leading to improvements in sperm count and testosterone levels in some individuals (NIH).
However, it's important to note that for many conditions, newer, more potent GnRH agonists (which cause initial stimulation followed by prolonged suppression) or antagonists (which directly block GnRH receptors) have largely replaced gonadorelin due to their more convenient dosing schedules and often stronger or more predictable effects. While the foundational role of gonadorelin in understanding the HPG axis is well-established, its current clinical use for broad applications in areas like muscle gain is not supported by mainstream medical evidence or clinical guidelines (Examine.com). Research connecting gonadorelin directly to improved muscle mass often refers to its role in addressing underlying hormonal deficiencies that, when corrected, might indirectly support healthy muscle function, rather than as a direct anabolic agent.
Like all medications, gonadorelin can cause side effects, though not everyone experiences them. The most common side effects are often related to the site of injection, such as pain, swelling, or redness. Other transient side effects can include flushing, lightheadedness, or nausea. More serious, but less common, side effects include hypersensitivity reactions, which can range from skin rashes to more severe allergic reactions such as anaphylaxis.
In therapeutic applications, particularly with pulsatile administration intended to stimulate gonadotropin release, side effects may also include effects related to hormonal fluctuations. For example, in women, ovarian hyperstimulation syndrome (OHSS) is a rare but serious complication, characterized by enlarged ovaries, fluid accumulation, and potentially blood clots. In men, supraphysiological levels of testosterone, if induced, could lead to acne, mood changes, or gynecomastia. However, these are typically associated with dysregulation of the HPG axis, rather than direct effects of gonadorelin itself when used appropriately.
Headache is also reported by some individuals after administration. Because gonadorelin influences the endocrine system, careful monitoring by a healthcare professional is essential to identify and manage any potential adverse effects. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Individuals with known hypersensitivity or allergic reactions to gonadorelin or any of its components should avoid its use. Special caution is advised for individuals with a history of allergies or asthma, as they may be at increased risk of hypersensitivity reactions. When used diagnostically or therapeutically, particularly in women, there is a risk of ovarian hyperstimulation syndrome (OHSS), which can be severe and life-threatening. Symptoms of OHSS include severe abdominal pain, bloating, nausea, vomiting, diarrhea, and decreased urination. Patients undergoing treatment that stimulates ovulation should be closely monitored for signs of OHSS. Use in pregnant or breastfeeding women is generally not recommended unless specifically indicated and supervised by a clinician, due to potential effects on fetal development or transfer into breast milk. Gonadorelin should be used with caution in patients with conditions that could be exacerbated by changes in sex hormone levels. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Gonadorelin is contraindicated in individuals with known hypersensitivity to gonadorelin or to any of the excipients in the formulation. It is generally contraindicated in pregnancy and lactation, except when specifically indicated under strict medical supervision and careful risk-benefit assessment. In women, gonadorelin should not be used in cases of ovarian cysts not due to polycystic ovarian syndrome, or in unexplained vaginal bleeding until a diagnosis is established. It is also contraindicated in sex hormone-dependent tumors. In conditions where stimulation of the reproductive axis would be detrimental, such as certain hormone-sensitive cancers (e.g., prostate cancer, some breast cancers), the use of gonadorelin or any GnRH analog is typically contraindicated or used in a suppressive (antagonist/agonist) manner that differs from its stimulatory role. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Care should be taken when gonadorelin is co-administered with other medications that affect the reproductive system or hormone levels. For example, drugs that alter pituitary function or gonadal steroid levels (e.g., sex steroids, clomiphene citrate) may interfere with the expected response to gonadorelin, either in diagnostic testing or therapeutic applications. Concurrent use of other medications that influence the hypothalamic-pituitary-gonadal axis could potentially lead to unpredictable hormonal responses or modify the efficacy or safety profile of gonadorelin. It is also important to consider interactions with medications that affect electrolyte balance, particularly if ovarian hyperstimulation syndrome (OHSS) is a risk. Always inform your healthcare provider about all medications, supplements, and herbal products you are currently taking to avoid potential interactions. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Gonadorelin has a very short half-life, approximately 6 to 10 minutes, meaning it is rapidly cleared from the body. Due to its rapid degradation, gonadorelin is administered by injection. For diagnostic purposes, a single intravenous injection is typically given. When used therapeutically to stimulate gonadotropin release (e.g., for ovulation induction or spermatogenesis), it requires pulsatile administration, which means it is given in small, precisely timed doses over an extended period. This pulsatile delivery mimics the natural secretion pattern of GnRH from the hypothalamus. The specific timing and frequency are user-directed and must be set by a licensed clinician based on the specific condition being treated, the desired physiological response, and ongoing monitoring of hormone levels and clinical indicators. The administration frequency can range from every 60 to 120 minutes via a controlled infusion pump. Gonadorelin can be taken independently of food.
Source for this section: Sources for When should you take Gonadorelin?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Gonadorelin?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Gonadorelin
Gonadorelin is a research peptide. It is also known as GnRH. The references summarized come from NIH and PubMed records, FDA labeling where it exists, and Mayo Clinic patient material.
Gonadorelin is commonly discussed in the context of supporting testosterone, brain, and muscle. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Gonadorelin, it is typically administered by injection and it is typically taken null. Always follow the specific dose your clinician or the product label prescribes.
Gonadorelin carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
As a peptide, Gonadorelin can overlap with other supplements, prescription medicines, hormones and peptides. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Gonadorelin with no sign-up.
Whether Gonadorelin fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Gonadorelin. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Gonadorelin varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Gonadorelin depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Gonadorelin the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 638793(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/638793
Verify at
Publisher search links for Gonadorelin. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Gonadorelin?
Plain-text summary, safe to quote verbatim:
Gonadorelin is a synthetic decapeptide (a peptide consisting of ten amino acids) that is structurally and functionally identical to the naturally occurring gonadotropin-releasing hormone (GnRH). GnRH is produced by the hypothalamus in the brain and plays a crucial role in regulating the reproductive system.
Source: DoseRoutine — https://doseroutine.com/library/gonadorelin
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Gonadorelin — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/gonadorelin
What compounds are similar to Gonadorelin?
Others in the peptide category or studied for the same goals.
Which goals is Gonadorelin used for?
Other compounds studied for the same benefits as Gonadorelin.
Continue exploring
See every compound DoseRoutine catalogs for these goals.